roche receives tarceva approval

The link between Roche and Evotec leads to another drug which just recently got the EC ( European Commission )approval.


Recently, Roche received a boost with the European Commission (EC) approving Tarceva (erlotinib) for first-line use in patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). The drug is already marketed as a treatment for advanced lung cancer after platinum-based chemotherapy.

Roche is also in talks with the US Food and Drug Administration (FDA) to gain approval to use Tarceva as a first-line treatment in people with advanced EGFR (epidermal growth factor receptor) activating mutation-positive NSCLC.

And here it gets really interesting !

Moreover, the company is in talks to gain approval for the use of a companion diagnostic test to help identify patients with activating EGFR mutations, who are appropriate candidates for Tarceva.


If ADO is involved in these talks, it would open the revenue of three large new drug development/ applications for Roche and be a major source of royalties for Geoff and his team.
I'm convinced that Bouris was hired not because we do look at the remote likelihood of his negotiating skills to be needed some time in the future, but because they are needed for an ongoing discussion in its final stages

Bouris would have timed his entry into the company perfectly to
make sure that much of the furore coming from the completion of such a deal would fall back on his personal involvement.

Roche's Tarceva